Stock CRDL CARDIOL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Cardiol Therapeutics Inc. Stock

Equities

CRDL

CA14161Y2006

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
3.19 CAD -3.63% Intraday chart for Cardiol Therapeutics Inc. +4.93% +190.00%
May. 23 Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $8 From $6, Maintains Buy Rating MT
May. 14 Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure MT

Financials

Sales 2024 * - Sales 2025 * - Capitalization 226M 166M
Net income 2024 * -26M -19.04M Net income 2025 * -28M -20.5M EV / Sales 2024 * -
Net cash position 2024 * 18.78M 13.75M Net cash position 2025 * 13.62M 9.97M EV / Sales 2025 * -
P/E ratio 2024 *
-6.38 x
P/E ratio 2025 *
-10.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.44%
More Fundamentals * Assessed data

Chart Cardiol Therapeutics Inc.

Dynamic Chart

Latest news about Cardiol Therapeutics Inc.

Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $8 From $6, Maintains Buy Rating MT
Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure MT
HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target MT
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cardiol Therapeutics Inc. Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx? for Recurrent Pericarditis CI
Cardiol Therapeutics Receives Orphan Drug Designation From FDA for Lead Drug Candidate to Treat Pericarditis MT
Cardiol Therapeutics Enrolls Over 50% of Patients for Phase II ARCHER Trial in Acute Myocarditis MT
Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis CI
Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot CI
Cardiol Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cardiol Therapeutics Inc. Announces 50% Enrollment in Its Phase Ii Maveric-Pilot Study in Recurrent Pericarditis CI
Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction CI
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx? for the Treatment of Acute Myocarditis CI
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $6 From $5, Maintains Buy Rating MT
More news

Analyst Recommendations on Cardiol Therapeutics Inc.

Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $8 From $6, Maintains Buy Rating MT
HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target MT
Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $6 From $5, Maintains Buy Rating MT
Cantor Fitzgerald Lowers Price Target to Cardiol Therapeutics to $5 From $6, Maintains Overweight Rating MT
CARDIOL THERAPEUTICS : Raymond James Adjusts Cardiol Therapeutics PT to CA$5 From CA$4.50, Maintains Outperform Rating MT
More recommendations

Press releases Cardiol Therapeutics Inc.

Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) AQ
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics AQ
CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2024 (EXPRESSED IN CANADIAN DOLLARS) - Form 6-K PU
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 NE
Cardiol Therapeutics : Notice of Meeting and Record Date - Form 6-K PU
More press releases

News in other languages on Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. : Cardiol Therapeutics präsentiert seine Phase-II-Studie ARCHER beim World Congress on Acute Heart Failure 2024
Cardiol Therapeutics Inc. : Cardiol Therapeutics gibt Update zur Geschäftstätigkeit zum Jahresende 2023 bekannt
Cardiol Therapeutics Inc (von First Berlin Equity Research...
Cardiol Therapeutics Inc. : Cardiol Therapeutics schließt in seiner Phase-II-Pilotstudie MAvERIC zur Bewertung von CardiolRx bei wiederkehrender Perikarditis die Patientenrekrutierung ab
Cardiol Therapeutics Inc. : Cardiol Therapeutics erhält für seinen Hauptwirkstoffkandidaten zur Behandlung der Perikarditis die Zulassung als Orphan-Arzneimittel
More news

Quotes and Performance

1 day-3.63%
1 week+4.93%
Current month+14.75%
1 month+30.20%
3 months+27.60%
6 months+170.34%
Current year+190.00%
More quotes

Highs and lows

1 week
3.00
Extreme 3
3.35
1 month
2.41
Extreme 2.41
3.35
Current year
1.13
Extreme 1.13
3.35
1 year
0.89
Extreme 0.89
3.35
3 years
0.61
Extreme 0.61
6.19
5 years
0.61
Extreme 0.61
6.19
10 years
0.61
Extreme 0.61
8.49
More quotes

Managers and Directors - Cardiol Therapeutics Inc.

Managers TitleAgeSince
David Elsley FOU
 Founder - 17-01-18
Christopher Waddick DFI
 Director of Finance/CFO - 18-08-15
Kelly Narine CTO
 Chief Tech/Sci/R&D Officer - 20-09-30
Members of the board TitleAgeSince
David Elsley FOU
 Founder - 17-01-18
Jennifer Chao BRD
 Director/Board Member 54 22-03-14
Michael Willner BRD
 Director/Board Member 57 21-09-06
More insiders

Quotes

Date Price Change Volume
24-05-28 3.19 -3.63% 79,690
24-05-27 3.31 +2.80% 118,084
24-05-24 3.22 +5.57% 106,803
24-05-23 3.05 +2.35% 98,514
24-05-22 2.98 -1.97% 295,969

Delayed Quote Toronto S.E., May 28, 2024 at 04:00 pm EDT

More quotes

Company Profile

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
Sector
Biotechnology & Medical Research
Calendar
2024-06-26 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.19 CAD
Average target price
4.25 CAD
Spread / Average Target
+33.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CARDIOL THERAPEUTICS INC. Stock Cardiol Therapeutics Inc.
+190.00% 160M
MODERNA, INC. Stock Moderna, Inc.
+54.05% 58.71B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.31B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 39.2B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.4B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.98B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.51B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRDL Stock